BridgeMD
New treatment option for Coronary Artery Disease
Official title NOAC Therapy Guided by PARIS Risk Score and D-dimer in Patients With ACS After PCI
ClinicalTrials.gov ID: NCT05638867
What this study is testing
What is Aspirin + Clopidogrel + Rivaroxaban?
Aspirin + Clopidogrel + Rivaroxaban is an investigational medicine, given as an once-daily pill taken by mouth, being studied as a potential treatment for coronary artery disease.
Also referred to as Triple Antithrombotic Therapy.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The goal of this clinical trial is to compare short-term Triple Antithrombotic Therapy (DAPT + Rivaroxaban) followed by DAPT with standard DAPT in selected ACS patients with high ischemic risk. The main questions it aims to answer are: Whether the intervention is effective in reducing ischemic events Whether the intervention is safe from increasing bleeding events, especially severe or fatal ones Participants will be randomized to receive standard DAPT therapy for the entire study duration or low-dose rivaroxaban+DAPT for 3 months, followed by standard DAPT for the rest of the study duration.
- Phase 4: studies an already-approved treatment
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- Diagnosed with Acute Coronary Syndrome 1-7 days after initial symptom stabilization,
- Aged 18-65 years old,
- Elevated D-dimer levels (≥0.28 μg/ml) on admission or PARIS coronary thrombosis risk score ≥ 3 points,
- Received Percutaneous Coronary Intervention and not on non-oral anticoagulants,
- Indicated for dual antiplatelet medication
You likely can't join if
- Platelet level below 90 x10\^6
- Hemoglobin level is less than 11g/dL
- History of severe bleeding
- History of stroke/TIA
- Severe hepatic/renal insufficiency
- Indicated for anticoagulation
The study team makes the final eligibility decision.
Where it's taking place
- Beijing, Beijing Municipality, China
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Beijing, Beijing Municipality, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.